Ginkgo Bioworks Holdings, Inc. (DNA, Financial) saw its stock price increase by 5.21%, reaching $9.39 per share. The trading volume was 463,888 shares with a turnover rate of 0.83% and a price fluctuation of 7.51%.
According to its recent financial report, Ginkgo Bioworks recorded revenues of $56.21 million, a net loss of $217 million, an earnings per share (EPS) of -$4.23, and a gross profit of $25.16 million. The price-to-earnings (P/E) ratio stands at -0.52.
Among the six analysts covering the stock, 17% recommend buying, another 17% suggest holding, while 66% advise selling. Despite the uptick in its stock price, the biotechnology sector, where Ginkgo Bioworks is categorized, experienced an overall decline of 1.73%.
In the biotechnology field, other notable stocks included Ensysce Biosciences, Inc., Genprex, Inc., and Silexion Therapeutics, which showed significant gains. Ensysce Biosciences and Genprex, in particular, demonstrated high turnover rates of 5281.26% and 4721.13% respectively.
Ginkgo Bioworks operates as a cell programming platform, offering end-to-end services across various markets such as food, agriculture, pharmaceuticals, and industrial chemicals. The company is structured into two main divisions: Foundry and Biosecurity, with the latter accounting for most of its revenue through data analysis and service fees.
